On 3/4/24, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock suffered a major decline of -12.1%, closing at $6.22. Moreover, trading volume in this decline was exceptionally high at 270% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -6.2% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, ZVRA is expected to continue to be Value Creation neutral.
Zevra Therapeutics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Zevra Therapeutics has a very low Appreciation Score of 3 but a good Power Rating of 72, with the Negative Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment